A string of acquisitions were announced in the pharmaceutical sector during September, most notably Merck & Co's (NYSE: MRK) $11.5 billion buy of Acceleron Pharma.
Sanofi (Euronext: SAN), Roche (ROG: SIX), Novartis (NOV: VX) and AstraZeneca (LSE: AZN) were among pharma's other big names that were in acquisitive mode, as was Spanish plasma specialist Grifols (GRF: MC), which moved to take over its German rival Biotest.
The table below details the month's deals:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze